TachoSil Paediatric Liver Trial (TC-019-IN)

Liver Diseases Clinical Trial

Official title:

A Prospective, Multi-centre Phase III-b Study of TachoSil in Paediatric Patients Scheduled for Resection of the Liver With or Without Segmental Liver Transplantation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00365248
• Other study ID #: TC-019-IN
• Secondary ID: 2004-005028-42
• Status: Completed
• Phase: Phase 3
• First received: August 16, 2006
• Last updated: May 4, 2012
• Start date: October 2005
• Est. completion date: May 2008

Study information

• Verified date: July 2008
• Source: Nycomed
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Health Service
• Study type: Interventional

Clinical Trial Summary

The overall objective is to assess the haemostatic efficacy and safety of TachoSil for control of local bleeding in paediatric patients undergoing surgical resection of the liver with our without segmental liver transplantation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: May 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 6 Years

Eligibility

Inclusion criteria:

1. Has the parent(s)/legal guardian given informed consent according to local requirements before any trial related activities?

2. Is the child above 4 weeks and below 6 years of age?

3. Has at least segmental resection (anatomical/non-anatomical) of the liver and primary haemostatic treatment been performed? or Has resection of the liver and placement of a segmental liver graft and primary haemostatic treatment been performed?

4. Is only minor, i.e. oozing, or moderate haemorrhage persisting after primary surgical haemostatic procedures of the major vessels (no pulsating arterial haemorrhage and/or major venous bleeding)?

All inclusion criteria must be answered "yes" for a child to participate in the study.

Exclusion criteria:

1. Was the child retransplanted or had liver transplantation in combination with other organs?

2. Was there anamnestic or laboratory evidence of congenital coagulation disorders including Haemophilia A or B and von Willebrand disease?

3. Has the child a history of allergic reactions after application of human fibrinogen, human thrombin and/or collagen of any origin?

4. Has the child fulminant hepatic failure, portal vein thrombosis or anamnestic or clinical evidence of cirrhotic condition of the liver, including cirrhosis due to genetic deficiency of a1 - Antitrypsin?

5. Did the child undergo an emergency operation?

6. Does the child participate in another clinical trial during the intra-operative phase?

7. Has any serious surgical complication occurred?

8. Has any fibrin glue haemostatic (including TachoSil ® ) been used on the target wound before the planned application of TachoSil ® ? To participate in the study all exclusion criteria must be answered "No" for a child having segmental resection. For a child having total hepatectomy and placement of a segmental liver transplant criteria 4 and 5 can be answered "Yes".

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Liver Diseases

Intervention

Drug:
• Fibrinogen human (TachoSil)
Resection of the liver with or without segmental liver transplantation

Locations

Country	Name	City	State
Denmark	Nycomed	Roskilde

Sponsors (1)

Lead Sponsor	Collaborator
Nycomed

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective is to collect data on efficacy, i.e. intra-operative haemostasis, and safety of TachoSil ® as treatment to control local bleeding in children undergoing surgical resection of the liver with or without segmental transplantation.		7½ months	No